Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
FATE
FATE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
FATE News
FT819 Achieves Significant Clinical Responses in Active SLE Patients Without Conditioning Chemotherapy
31m ago
Newsfilter
Fate Therapeutics Selected for FDA CDRP Program to Accelerate FT819 Development
6d ago
Newsfilter
Avaí Bio Initiates α-Klotho Cell Production Phase
Mar 27 2026
PRnewswire
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
Mar 27 2026
Newsfilter
Avaí Bio Initiates Production of α-Klotho Cell Bank
Mar 18 2026
Globenewswire
Avaí Bio Advances Cell Therapy Production Milestone
Mar 03 2026
PRnewswire
Avaí Bio Advances α-Klotho Cell Production Milestone
Mar 03 2026
Newsfilter
Fate Therapeutics Reports Q4 2025 Revenue and Financial Position
Feb 26 2026
seekingalpha
FT819 CAR T-Cell Therapy Achieves Significant Milestone
Feb 26 2026
Newsfilter
Fate Therapeutics Inc. Forecasts Operating Runway Until End of 2027, Backed by $205 Million in Cash and Investments
Feb 26 2026
moomoo
Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate
Feb 16 2026
Newsfilter
Avant Technologies Leads Transformation in Healthcare Market
Jan 26 2026
PRnewswire
Avant Technologies Leads Medical Innovation with Next-Gen Treatments
Jan 26 2026
Newsfilter
Avant Technologies Unveils Cell Encapsulation Tech to Address 589 Million Diabetes Patients' Needs
Jan 23 2026
Globenewswire
Avant Technologies Unveils Cell Encapsulation Tech, Tapping into Diabetes Market Potential
Jan 23 2026
Newsfilter
Needham Maintains Hold Rating on Fate Therapeutics
Oct 27 2025
Benzinga
Show More News
